Key Takeaway: Agomab has announced positive interim results from its Phase 2a trial of AGMB-129 for fibrostenosing Crohn's disease. The treatment successfully met all primary and secondary endpoints after 12 weeks in a study involving 44 patients. Detailed results will be shared at an upcoming scientific conference, with full results expected in Q4 2025.
Market Sentiment Analysis
POSITIVE FACTORS
AGMB-129 met all primary and secondary endpoints.
Positive interim results from 44 patients after 12 weeks.
Future presentation of detailed results at a scientific conference.
Open-label extension study has been initiated.
Full Press Release Details
— AGMB-129 hit all primary and secondary endpoints in interim read-out from 44 patients after 12 weeks treatment — Detailed interim STENOVA results to be presented at future scientific conference — STENOVA clinical trial on track to report full results in the fourth quarter of 2025 — Open-label extension study initiated
Frequently Asked Questions
What are the results of the AGMB-129 trial?
AGMB-129 met all primary and secondary endpoints in the Phase 2a trial.
How many patients were involved in the AGMB-129 study?
The study involved 44 patients treated for 12 weeks.
When will full results of the trial be available?
Full results are expected to be reported in the fourth quarter of 2025.
Is there an extension study for AGMB-129?
Yes, an open-label extension study has been initiated.
Where will detailed interim results be presented?
Detailed results will be presented at a future scientific conference.